<DOC>
	<DOCNO>NCT00556348</DOCNO>
	<brief_summary>To report short term anatomic visual acuity response intravitreal injection bevacizumab ( Avastin , Roche , Rio de Janeiro , Brazil ) patient choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Choridal Neovascularization Secondary Age-Related Macular Degeneration</brief_title>
	<detailed_description>We conduct retrospective study 500 eye choroidal neovascularization secondary age-related macular degeneration treat least two ( initial one month ) intravitreal injection 1.25 mg bevacizumab follow-up least 2 month . Patients underwent Snellen visual acuity testing , optical coherence tomography ( OCT ) image ophthalmoscopic examination baseline follow-up visit .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age relate macular degeneration Juxtafoveal Subfoveal CNVM : Recurrent CNVM follow PDT TTT IVTA . Patient could afford PDT , Macugen Lucentis FDA approve . Myopic CNVM , Idiopathic CNVM , Inflammatory CNVM condition associate CNVM . Refractory macular oedema due vein occlusion , Pseudophakia , Clinically significant macular oedema ( CSME ) etc . affect vision respond adequately usual treatment method . Proliferative diabetic retinopathy , nonresolving vitreous haemorrhage PDR . Patients poor compliance Patients uncontrolled diabetes hypertension medical condition increase risk complication like recent history Stroke myocardial infraction ( &lt; one year ) . ( Physician clearance obtain patient ) . Patients undergone major surgery 28 day , exclude study also suspend prior elective surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>AMD</keyword>
	<keyword>Complications</keyword>
	<keyword>Visual acuity</keyword>
	<keyword>OCt</keyword>
	<keyword>Age Macular Degeneration</keyword>
</DOC>